Market Overview

Oppenheimer Downgrades Marinus Pharmaceuticals, Removes Price Target On Disappointing Epilepsy Study Results

Oppenheimer Downgrades Marinus Pharmaceuticals, Removes Price Target On Disappointing Epilepsy Study Results

Oppenheimer has downgraded Marinus Pharmaceuticals Inc (NASDAQ: MRNS) to Perform after the company's first Phase 3 epilepsy study for adult focal onset seizures failed to meet its primary endpoint.

Even though company indicated there were certain sub-demographics of better responders in the greater studied populations, it effectively shut the door on any possibility of moving ganaxolone ahead in adult epilepsy.

Marinus will now focus on ganaxolone for indications within Status Epilepticus and pediatric orphan.

Related Link: In Wake Of Orlando Shooting, Here Are Some Positive Business Responses

"As we only took into account the adult epilepsy indication in our valuation, and left any contribution from the other programs as upside, we are moving to a Perform rating," analyst Rohit Vanjani wrote in a note.

Vanjani said his 2016/2017 EPS estimates move to ($1.55)/($1.10) from prior ($1.57)/($1.22). The analyst also removed his $17 price target.

At the time of writing, shares of Marinus Pharma plunged more than 11 percent to $1.44. The stock touched a new 52-week low of $1.43.

Latest Ratings for MRNS

Sep 2020Truist SecuritiesInitiates Coverage OnBuy
Sep 2020HC Wainwright & Co.MaintainsBuy
Sep 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for MRNS
View the Latest Analyst Ratings


Related Articles (MRNS)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Downgrades Health Care Price Target Analyst Ratings Tech Trading Ideas

Latest Ratings

FBTruist SecuritiesMaintains310.0
GOOGLDeutsche BankMaintains2,250.0
FBWells FargoMaintains330.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at